Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Brain Neoplasms 10Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Lung Neoplasms 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Central Nervous System Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Melanoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Renal Cell 2Astrocytoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thymus Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Salivary Gland Neoplasms 1

Interventions

Irinotecan 31Paclitaxel 27Gemcitabine 27Cisplatin 25Docetaxel 20Oxaliplatin 16Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 13Capecitabine 12Bortezomib 10Early Intervention, Educational 9Topotecan 8Taxes 83-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Temozolomide 6Sorafenib 6Immunohistochemistry 6Immunoenzyme Techniques 6Bevacizumab 67-hydroxystaurosporine 6tanespimycin 5Pharmacogenomic Testing 5Pemetrexed 5Magnetic Resonance Spectroscopy 5Filgrastim 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Unspecified Adult Solid Tumor, Protocol Specific × alovudine × Clear all
NCT02146222 2019-11-18

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors

University of Wisconsin, Madison

Phase 1 Completed
14 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡